Tscan Therapeutics is trading at $0.70, up +5.67% in pre-market, with no fresh company-specific catalyst identified.
- No announcement, earnings release, or filing explaining the September 2, 2026 movement was identified.
- The latest major update was August 12, 2026 second-quarter results; the Phase 3 ALLOHA-2 dosing announcement came July 29, 2026, making both relatively stale catalysts.
- Broader indexes were lower, so global sentiment does not clearly explain the gain.